News
CPIX
1.550
-4.91%
-0.080
Weekly Report: what happened at CPIX last week (0408-0412)?
Weekly Report · 20h ago
Weekly Report: what happened at CPIX last week (0401-0405)?
Weekly Report · 04/08 09:11
Weekly Report: what happened at CPIX last week (0325-0329)?
Weekly Report · 04/01 09:11
Cumberland Pharmaceuticals Inc: Statement of changes in beneficial ownership of securities
Press release · 03/27 02:02
Weekly Report: what happened at CPIX last week (0318-0322)?
Weekly Report · 03/25 09:11
Weekly Report: what happened at CPIX last week (0311-0315)?
Weekly Report · 03/18 09:11
Cumberland Pharmaceuticals Full Year 2023 Earnings: US$0.44 loss per share (vs US$0.38 loss in FY 2022)
Cumberland Pharmaceuticals shares are down 14% from a week ago. In the last 12 months, the only revenue segment was Specialty Pharmaceutical Products contributing US$39.6m. The largest operating expense was Sales & Marketing costs, amounting to US$18.5m.
Simply Wall St · 03/15 11:16
Weekly Report: what happened at CPIX last week (0304-0308)?
Weekly Report · 03/11 09:11
Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) has US$12.8m of debt. The company uses debt to shore up its balance sheet, but has a positive free cash flow. Debt is a concern for shareholders, but the company does not have a heavy debt load. In the last year Cumberland Pharmaceutical's had a loss before interest and tax of US$5.6m. Despite its debt, the company has a strong balance sheet and has net cash. We are cautious of the company because of its modest revenue growth.
Simply Wall St · 03/07 11:01
CPIX Stock Earnings: Cumberland Reported Results for Q4 2023
Cumberland reported earnings per share of -11 cents. The company reported revenue of $9.35 million. The stock was down 2.7% in the after-hours trading session on Thursday. The shares of Cumberland were down 2% in after- hours trading.
Investorplace · 03/06 02:52
*Cumberland Pharma 4Q Loss/Shr 44c >CPIX
Dow Jones · 03/05 21:17
*Cumberland Pharma 4Q Rev $9.35M >CPIX
Dow Jones · 03/05 21:16
Cumberland Pharmaceuticals Non-GAAP EPS of $0.17, revenue of $40M
Seeking Alpha · 03/05 21:13
Press Release: Cumberland Pharmaceuticals Reports -2-
The company's portfolio of FDA-approved brands includes Acetadote, Caldolor and Kristalose. Cumberland's products are approved for the treatment of pain and fever. The company has a series of clinical programs underway to develop new products for other conditions. The products are marketed in the United States.
Dow Jones · 03/05 21:05
Press Release: Cumberland Pharmaceuticals Reports Annual 2023 Financial Results
Cumberland Pharmaceuticals Inc. Reports Annual 2023 Financial Results. The company's product portfolio of FDA-approved brands delivered combined revenues of $40 million in 2023. The FDA approved expanded labeling for Cumberland's Caldolor product to include use in infants. Cumberland will report its 2023 financial results and provide a conference call on March 5, 2024.
Dow Jones · 03/05 21:05
Cumberland: Q4 Earnings Snapshot
Cumberland Pharmaceuticals Inc. Reported a loss of $6.3 million in its fourth quarter. The pharmaceutical company posted revenue of $9.4 million in the period. For the year, the company reported a Loss of 44 cents per share. The company is based in Nashville, Tennessee.
Barchart · 03/05 15:24
Earnings Scheduled For March 5, 2024
Target is estimated to report quarterly earnings at $2.22 per share on revenue of $29.33 billion. Companies reporting before the bell include NIO, Target and Nordstrom. Companies expected to report earnings for their fourth quarter include Vivid Seats, V2X and NIO.
Benzinga · 03/05 10:00
Weekly Report: what happened at CPIX last week (0226-0301)?
Weekly Report · 03/04 09:11
Weekly Report: what happened at CPIX last week (0219-0223)?
Weekly Report · 02/26 09:12
Weekly Report: what happened at CPIX last week (0212-0216)?
Weekly Report · 02/19 09:12
More
Webull provides a variety of real-time CPIX stock news. You can receive the latest news about Cumberland Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About CPIX
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote injection, for the treatment of acetaminophen poisoning; Caldolor injection, for the treatment of pain and fever, Kristalose for oral solution, a prescription laxative, for the treatment of constipation, and Omeclamox-Pak, oral, for the treatment of Helicobacter pylori infection and related duodenal ulcer disease. Its brands also include Sancuso transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia, and Vibativ injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia.